AI companies such as OpenAI and Anthropic have long focused on building tools that can write code that will speed up software ...
Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback